ACTRN12620000685910终止1 期
A randomized, double-blind, placebo-controlled single and multiple ascending dose study to test the safety, tolerability, pharmacokinetics and pharmacodynamics of NT-0167 in healthy volunteers
odThera0 个研究点目标入组 41 人开始时间: 2020年6月17日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 41
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1.Signed informed consent and willing and able to comply with the study protocol;
- •2.Healthy men or women of non-child bearing potential (WNCBP), 18 to 55 years of age (inclusive) at screening. The health status is verified by absence of evidence of any clinically significant active or uncontrolled chronic disease following a detailed medical history, a complete physical examination including vital signs, laboratory measurements, and 12-lead ECG;
- •3.Female subjects must be of non-childbearing potential in accordance with one of the following definitions:
- •Surgically sterile (by hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy) as documented by a surgical report or by ultrasound, or
- •Post-menopausal (age-appropriate spontaneous amenorrhoea for equal to or greater than 12 months and follicle-stimulating hormone (FSH) equal to or greater than 40 IU/mL together with the absence of oral contraceptive use for greater than 12 months);
- •4.Male volunteers agree to use barrier protection when they engage in sexual relations with women of child-bearing potential (WOCBP) or lactating women for the duration of their participation in the study and until 90 days after EOS.
- •5.Body mass index (BMI) between 18 and 32 kg/m2, inclusive, and with a minimum bodyweight of 50 kg;
- •6.Has the ability to communicate well with the Investigator and willing to comply with the study restrictions.
- •7.Have the intention to be reachable by mobile phone or e-mail during the whole study period.
排除标准
- •1.Lactating females;
- •2.Female volunteers with a positive pregnancy test at screening or baseline prior to IMP administration;
- •3.Evidence (including symptoms, physical signs, and/or laboratory values) of any active or chronic disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator;
- •4.Any confirmed or suspected disease or condition associated with immune system impairment, including auto-immune diseases, HIV, asplenia or recurrent severe infections.
- •5.Use of chronic (more than 14 days) immunosuppressant or immunomodulatory drugs within the 6 months prior to IMP administration, or isolated (non-chronic) use within 30 days prior to IMP administration;
- •6.Any history of severe allergic reaction(s);
- •7.Any confirmed drug hypersensitivity reactions (including skin reactions or anaphylaxis), or other known clinically significant allergies;
- •8.History of clinically significant systemic disorders including haematological, renal, endocrine, gastrointestinal, hepatic, cardiovascular, pulmonary, dermatological and neurological disorders, or other conditions which could interfere with the interpretation of the study results or compromise the health of the volunteers;
- •9.Any history of psychiatric condition that may affect participation in the study or preclude compliance with the protocol;
- •10.Receipt of any vaccination, other than an influenza vaccine, within 3 months of IMP administration.
- •11..Participation in an investigational drug, vaccine or device study within 3 months prior to first dosing or plans to participate in other investigational drug, vaccine or device research during the study period.
- •12.Any nutrients known to modulate CYP enzymes activity (e.g., grapefruit or Seville orange containing products or quinine containing drinks (tonic water or bitter lemon)) will not be permitted from 5 days before dosing until the final PK sample is collected;
- •13.Donation (or loss) of whole blood of 400 ml or more during the 12 weeks prior to IMP administration;
- •14..Donation of plasma or platelets during the 8 weeks prior to IMP administration;
- •15..Any other known factor, condition, or disease that, in the opinion of the Investigator, might interfere with treatment compliance, study conduct or interpretation of the results, or may compromise volunteer safety.
研究者
相似试验
已完成
不适用
A randomized, double-blind, placebo-controlled single and multiple ascending dose study of the safety, tolerability and pharmacokinetics of oral doses of SAR443122 in healthy adult subjects.Auto immune disease10003816NL-OMON48479Sanofi-aventis97
已完成
不适用
phase I clinical trial to investigate the safety, tolerability, and pharmacokinetics of HY209 gel as an possible treatment option for atopic dermatitisDiseases of the skin and subcutaneous tissueKCT0003988Shaperon56
已完成
不适用
A randomized, double-blind, placebo-controlled single and multiple ascending dose study to test the safety, tolerability, pharmacokinetics and pharmacodynamics of NT-0167 in healthy volunteersinflammatory disorders and neurodegenerative diseasesinflammatory disordersneurodegenerative diseasesNL-OMON49667odThera80
已完成
不适用
A randomized, double blind, placebo-controlled single ascending dose study on the safety, tolerability, pharmacokinetics and pharmacodynamics of ACT017 in healthy volunteersstrokecerebral infarction10007963NL-OMON44567Acticor Biotech SAS48
已完成
不适用
Evaluation of the effect of choline-stabilized orthosilicic acid on the symptoms of knee osteoarthritisMusculoskeletal DiseasesGonarthrosis [arthrosis of knee]Knee osteoarthritisISRCTN10096951Bio Minerals NV227